Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Baylor Breast Care Center GlaxoSmithKline |
---|---|
Information provided by: | Baylor Breast Care Center |
ClinicalTrials.gov Identifier: | NCT00206427 |
We want to learn whether GW572016 is effective in breast cancers that have HER2.
Condition | Intervention | Phase |
---|---|---|
Breast Cancer |
Drug: GW572016 Drug: lapatinib |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Neoadjuvant Phase II Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients: Biologic Correlative Study |
Estimated Enrollment: | 55 |
Study Start Date: | August 2004 |
Estimated Study Completion Date: | September 2010 |
Estimated Primary Completion Date: | August 2010 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Anne Pavlick, CRC | 713-798-1975 | acpavlick@bcm.edu |
Contact: Brenda Reusser, BA | 713-798-1929 | breusser@bcm.tmc.edu |
United States, California | |
USC Norris Comprehensive Cancer Center | Recruiting |
Los Angeles, California, United States, 90033 | |
Contact: Ashai Zeno, MPH 323-865-0454 ashai_z@ccnt.norccc.usc.edu | |
Principal Investigator: Darcy Spicer, MD | |
United States, New Mexico | |
University of New Mexico | Recruiting |
Albuquerque, New Mexico, United States, 87131 | |
Contact: Susan Lopez 505-272-5404 slopez@salud.unm.edu | |
Contact: Ann Parsons 505-272-2776 aparsons@salud.unm.edu | |
Principal Investigator: Melanie Royce, MD | |
United States, Texas | |
Baylor Breast Center | Recruiting |
Houston, Texas, United States, 77030 | |
Contact: Anne Pavlick, BS 713-798-1975 acpavlic@bcm.tmc.edu | |
Contact: Amber Froehlich, BA 713-798-7814 amberf@bcm.edu | |
Principal Investigator: Jenny Chang, MD | |
Sub-Investigator: Powel Brown, MD | |
Sub-Investigator: C Kent Osborne, MD | |
Sub-Investigator: Susan Hilsenbeck | |
Sub-Investigator: M. Carolina Gutierrez | |
Sub-Investigator: Garrett Lynch, MD | |
Sub-Investigator: Mothaffar Rimawi, MD | |
Baylor Breast Center | Recruiting |
Houston, Texas, United States, 77030 | |
Contact: Brenda L Reusser, BA 713-798-7814 breusser@breastcenter.tmc.edu | |
Contact: Anne Pavlick, CRC 713-798-1975 acpavlick@bcm.edu | |
Sub-Investigator: Powell Brown, MD | |
Sub-Investigator: Garrett Lynch, MD | |
Sub-Investigator: Kent Osborne, MD | |
Sub-Investigator: Mothafar Rimawi, MD | |
Sub-Investigator: Yee-Lu Tham, MD |
Principal Investigator: | Jenny Chang, MD | Baylor Breast Center |
Responsible Party: | Baylor College of Medicine, Breast Center ( Jenny Chang, MD ) |
Study ID Numbers: | H 15430, Neoadjuvant GW572016 |
Study First Received: | September 14, 2005 |
Last Updated: | January 5, 2009 |
ClinicalTrials.gov Identifier: | NCT00206427 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Advanced Breast Cancer Neoadjuvant HER2 |
Skin Diseases Breast Neoplasms Lapatinib Protein Kinase Inhibitors Breast Diseases |
Neoplasms Neoplasms by Site Molecular Mechanisms of Pharmacological Action Skin Diseases Antineoplastic Agents Therapeutic Uses |
Breast Neoplasms Enzyme Inhibitors Lapatinib Protein Kinase Inhibitors Pharmacologic Actions Breast Diseases |